The Anglo-Swedish drugmaker is expanding its strategic partnership with the two Stockholm institutions to speed up research in cardiometabolic and kidney diseases.

The four projects cover:

  • Obesity and the biology of adipose tissue
  • New therapeutic targets for advanced liver fibrosis and cirrhosis
  • Clinical epidemiology in chronic kidney disease
  • Risk modeling, evaluation, and monitoring of treatment response in liver disease

Obesity is a new research area for the partnership. The project will look at how adipose tissue interacts with the liver, kidneys, and other organs, and how it affects metabolism, inflammation, and disease progression. In the long term, the findings could lead to new drugs, biomarkers, diagnostic methods, and treatments.

“This long-term partnership reflects our commitment to investing in world-leading research and building on the unique expertise found in Swedish academia, healthcare, and the life science sector. Together, we can turn research into innovation and lay the foundation for the next generation of treatments,” says Regina Fritsche Danielson, Senior Vice President and Head of Research and Early Clinical Development at AstraZeneca.

“High-quality research is essential if we are to better understand complex diseases and develop the treatments of the future. By bringing together academia, healthcare, and industry, we are creating a strong environment for groundbreaking translational research,” says Annika Östman Wernerson, President of Karolinska Institutet.

“As one of the world’s leading hospitals, we have both a responsibility and an opportunity to help shape the healthcare of the future. That is why we are working hard to integrate clinical research directly into care. Our collaboration with AstraZeneca is an important part of that work, and therefore for our patients,” says Christophe Pedroletti, Hospital Director at Karolinska University Hospital.